Q-omics provides the consensus-scored VPS9D1 profile across patient tissues and cancer cell-line models. VPS9D1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VPS9D1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, VPS9D1 RNA expression shows 17,379 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where VPS9D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS9D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS9D1 survival associations across molecular data types. VPS9D1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS9D1 RNA expression–survival associations across cancer types. High VPS9D1 expression shows unfavorable associations in ACC, KIRC, LUAD and LIHC, but favorable associations in KIRP and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for VPS9D1 RNA expression.
This table summarizes VPS9D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VPS9D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS9D1 shows lower tumor expression in HNSC and higher tumor expression in LIHC, KIRP, LUAD, KICH and CHOL. The LIHC box plot shows higher VPS9D1 RNA expression in tumor versus normal tissue (log2 FC = +0.715, t-test p < 0.001).
This table shows molecular features associated with VPS9D1 in patient tissues and cancer cell lines. In patient samples, VPS9D1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS9D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
